What was known before {#section21-2054358118780372}
=====================

Patients on dialysis have a high risk of hospitalization relative to the general population. Hospitalization rates of dialysis patients in the United States have been tracked for many years. In contrast, there are limited data on hospitalizations of dialysis patients in Canada.

What this adds {#section22-2054358118780372}
==============

This is the first national study to describe the important issue of hospitalizations in Canadian chronic dialysis patients. Pediatric, Indigenous, and female patients are at higher risk for hospitalizations, and the initial weeks postdialysis initiation represent a high-risk transitional period.

Introduction {#section23-2054358118780372}
============

Patients on dialysis have an extremely high risk of requiring admission to an acute care hospital (hospitalization) relative to the general population.^[@bibr1-2054358118780372]^ Over the past few decades, the dialysis population has shifted demographically to older patients with a higher number of comorbidities.^[@bibr2-2054358118780372]^ This has led to concern that the acute hospitalization rate may rise, which would place further strain on existing health care resources. Hospitalizations denote a critical inflection point for the health of dialysis patients, as they are associated with multiple adverse clinical outcomes.^[@bibr3-2054358118780372][@bibr4-2054358118780372]-[@bibr5-2054358118780372]^

Hospitalizations in dialysis patients have been tracked in the United States for many years. Data from the 2016 United States Renal Data System (USRDS) annual report showed that patients with end-stage kidney disease (ESKD) are admitted to hospital, on average, nearly twice per year, and inpatient treatment accounts for approximately 40% of all Medicare spending for dialysis patients.^[@bibr6-2054358118780372]^ In contrast, there are limited data on the incidence and patient risk factors associated with hospitalizations in dialysis patients in Canada. It remains unclear whether the risk of hospitalization differs between the United States and Canada. There are key practice differences between the 2 countries, such as a higher prevalence of peritoneal dialysis (PD) use, broader access to predialysis care, and higher use of central venous catheters (CVC) in Canada,^[@bibr7-2054358118780372]^ which may all modify hospitalization risks. To date, hospitalizations of dialysis patients in Canada have not been reported at a national level. Prior Canadian studies have examined only provincial or single-center level data, or have focused solely on infection-related hospitalizations.^[@bibr8-2054358118780372][@bibr9-2054358118780372][@bibr10-2054358118780372]-[@bibr11-2054358118780372]^ Recognizing the negative impact of hospitalizations on dialysis patient quality of life and the enormous cost burden on finite health care budgets, further studies are needed to better understand this important issue. The first step in developing strategies to improve health outcomes and reduce health care utilization in Canadian dialysis patients is a population-based study that considers different factors (demographic, comorbid disease, and dialysis-related) which may be associated with all-cause and infection-related hospitalizations.

Methods {#section24-2054358118780372}
=======

Design and Setting {#section25-2054358118780372}
------------------

We conducted a population-based retrospective cohort study that included provinces and territories across Canada using health care databases housed at the Canadian Institute for Health Information (CIHI). Hospitalization data could not be linked for Manitoba and Quebec, so these provinces were excluded. The study was conducted according to a prespecified protocol approved by the Hamilton Integrated Research Ethics Board. The reporting of this study follows the REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) guidelines for observational studies (see [Appendix A](http://journals.sagepub.com/doi/suppl/10.1177/2054358118780372) in Supplementary Material).^[@bibr12-2054358118780372]^

Data Sources {#section26-2054358118780372}
------------

The Canadian Organ Replacement Register (CORR) is a validated registry that includes demographics, comorbidities, dialysis modality and related outcomes, vascular access subtype, transplantation and mortality data on all ESKD patients in Canada.^[@bibr13-2054358118780372],[@bibr14-2054358118780372]^ The ESKD is defined by the requirement for dialysis for at least 90 consecutive days. The CIHI discharge abstract database (DAD) contains diagnostic and procedure information on all hospitalizations. Hospitalization events and the reason for hospitalization were extracted from the CIHI-DAD. For the province of Ontario, hospitalization data were supplemented with the Ontario Mental Health Reporting System (OMHRS). The data sets were linked using unique encoded identifiers and analyzed at CIHI.

Study Cohort {#section27-2054358118780372}
------------

We included all incident chronic dialysis patients with a dialysis start date between January 1, 2005, and March 31, 2014. Dialysis patients with nonlinkable health care numbers, patients residing in Quebec and Manitoba, patients simultaneously on both hemodialysis (HD) and PD, and those with a kidney transplant prior to dialysis initiation were excluded.

Hospitalizations {#section28-2054358118780372}
----------------

The primary outcomes of interest were all-cause hospitalizations and dialysis-specific infection-related hospitalizations, ie, related to a vascular access device, septicemia, or peritonitis (diagnostic codes for infection-related hospitalizations are detailed in [Appendix B](http://journals.sagepub.com/doi/suppl/10.1177/2054358118780372) in Supplementary Material). The cause of hospitalization was determined using the most responsible diagnosis recorded in the DAD, which is the single diagnosis or condition described as being most responsible for the patient's length of stay in hospital. If there were multiple diagnoses or conditions, the one most responsible for the greatest use of resources was recorded.

Statistical Analysis {#section29-2054358118780372}
--------------------

Crude rates for all-cause hospitalization, infection-related hospitalization, and in-hospital mortality were determined per patient year (PPY) after dialysis initiation at 7 and 30 days, and at 3, 6, and 12 months, and reported by age group (0-17, 18-44, 45-64, ⩾65 years). A stratified, gamma-distributed frailty model was used to assess repeated hospital admissions and to appropriately handle the statistical dependence of hospitalization events within individuals, and estimate the hazard ratio (HR) attributed to each covariate of interest. The frailty model was stratified by 4 regions: Atlantic Canada; Ontario; Saskatchewan, Alberta, the Northwest Territories, and Nunavut; and British Columbia and Yukon. Patients were followed from their date of dialysis initiation until the first of kidney transplantation, withdrawal from dialysis, loss to follow-up, death, or the end of study follow-up (March 31, 2015). Demographics, comorbidities, cause of ESKD, and dialysis care type (in-center vs home) were recorded at the time of registration into CORR (ie, time of registration as a chronic dialysis patient). Dialysis modality (PD vs HD) was determined at registration into CORR and over the duration of follow-up, recognizing that many patients change dialysis modality over time. The number of predialysis hospitalizations was ascertained in the 6 months prior to dialysis initiation. Hospitalizations with an admission date prior to or on the date of dialysis initiation were treated as predialysis hospitalizations. As such, patients admitted to hospital at the time of dialysis initiation would first have to be discharged to be at risk for a hospitalization event.

The association of the following a priori covariates with all-cause hospitalization and infection-related hospitalization was determined: age (0-17, 18-44, 45-64, 65-74, ⩾75 years), sex, race (Asian, Indian subcontinent, Indigenous, black, Caucasian, other or unknown), neighborhood income quintile (derived from postal code), dialysis care type (home vs in center), cause of ESKD (glomerulonephritis, diabetes, renal vascular disease, congenital/hereditary, other, uncertain), comorbidities (cardiovascular disease, congestive heart failure, peripheral vascular disease, diabetes, malignancy, chronic obstructive pulmonary disease, hypertension defined by the need for antihypertensive therapy), time in hospital during the 6 months prior to dialysis initiation (treated as a continuous variable per week of cumulative hospital time), and dialysis modality (PD vs HD). Dialysis modality over follow-up was analyzed as a time-varying covariate.

Results {#section30-2054358118780372}
=======

Baseline Characteristics {#section31-2054358118780372}
------------------------

The final study cohort included 38 369 incident chronic dialysis patients ([Supplementary Figure 1](http://journals.sagepub.com/doi/suppl/10.1177/2054358118780372)). Baseline characteristics are detailed in [Table 1](#table1-2054358118780372){ref-type="table"}. Most patients were age 45 to 64 years (33.4%), male (61.0%), Caucasian (70.3%), and from the lowest income quintile (25.0%). The majority of patients were on HD (80.2%) and performed dialysis in-center (80.4%). The most common cause of ESKD was diabetes (36.1%). There was a high prevalence of hypertension (76.5%), cardiovascular disease (29.6%), and congestive heart failure (22.8%). Most patients had 1 or more hospitalizations in the 6 months prior to dialysis initiation (66.4%).

###### 

Patient Characteristics.

![](10.1177_2054358118780372-table1)

  Characteristic                                                                        Number of patients (%)
  ------------------------------------------------------------------------------------- ------------------------
  Age group                                                                             
   0-17                                                                                 281 (0.7)
   18-44                                                                                4097 (10.7)
   45-64                                                                                12 798 (33.4)
   65-74                                                                                9811 (25.6)
   ⩾75                                                                                  11 382 (29.7)
  Female sex                                                                            14 979 (39)
  Race                                                                                  
   Caucasian                                                                            26 988 (70.3)
   Asian                                                                                2554 (6.7)
   Indian subcontinent                                                                  2044 (5.3)
   Indigenous                                                                           1777 (4.6)
   Black                                                                                1430 (3.7)
   Other or unknown                                                                     3576 (9.3)
  Income quintile^[a](#table-fn2-2054358118780372){ref-type="table-fn"}^                
   5 (high)                                                                             5588 (14.6)
   4                                                                                    6764 (17.6)
   3                                                                                    7325 (19.1)
   2                                                                                    8386 (21.9)
   1 (low)                                                                              9587 (25.0)
   Missing                                                                              719 (1.9)
  Province/territory^[b](#table-fn3-2054358118780372){ref-type="table-fn"}^             
   British Columbia                                                                     6696 (17.5)
   Alberta                                                                              4483 (11.7)
   Saskatchewan                                                                         1729 (4.5)
   Ontario                                                                              21 743 (56.7)
   New Brunswick                                                                        1032 (2.7)
   Nova Scotia                                                                          1437 (3.7)
   Prince Edward Island                                                                 193 (0.5)
   Newfoundland and Labrador                                                            1008 (2.6)
   Territories                                                                          48 (0.1)
  Modality^[c](#table-fn4-2054358118780372){ref-type="table-fn"}^                       
   HD                                                                                   30 777 (80.2)
   PD                                                                                   7592 (19.8)
  Care location^[c](#table-fn4-2054358118780372){ref-type="table-fn"}^                  
   In center                                                                            30 860 (80.4)
   Home                                                                                 7509 (19.6)
  Cause of ESKD                                                                         
   Diabetes                                                                             13 863 (36.1)
   Renal vascular disease                                                               7104 (18.5)
   Glomerulonephritis                                                                   4924 (12.8)
   Uncertain                                                                            3035 (7.9)
   Congenital/hereditary                                                                2190 (5.7)
   Other                                                                                4963 (12.9)
   Missing                                                                              2290 (6.0)
  Comorbidities                                                                         
   Cardiovascular disease                                                               11 339 (29.6)
   Congestive heart failure                                                             8757 (22.8)
   Cerebrovascular disease                                                              4982 (13.0)
   Peripheral vascular disease                                                          6065 (15.8)
   Diabetes^[d](#table-fn5-2054358118780372){ref-type="table-fn"}^                      4982 (13.0)
   Malignancy                                                                           5061 (13.2)
   COPD                                                                                 4281 (11.2)
   Hypertension                                                                         29 336 (76.5)
  Predialysis hospitalizations^[e](#table-fn6-2054358118780372){ref-type="table-fn"}^   
   0                                                                                    12 910 (33.6)
   1                                                                                    16 070 (41.9)
   2                                                                                    5931 (15.5)
   3                                                                                    2150 (5.6)
   4                                                                                    817 (2.1)
   5                                                                                    313 (0.8)
   6                                                                                    98 (0.3)
   ⩾7                                                                                   80 (0.2)

*Note.* All variables are captured at the start of dialysis. HD = hemodialysis; PD = peritoneal dialysis; ESKD = end-stage kidney disease; COPD = chronic obstructive pulmonary disease.

Patient level household income is an estimate using neighborhood income levels.

Province/territory is determined by issuance of health card.

Dialysis modality and care location were determined at baseline. In-center care location was assigned to patients on HD or PD receiving total in-center care at the time of dialysis initiation.

The diabetes comorbidity variable excludes patients with a primary ESKD diagnosis of diabetes.

Denotes the number of hospital admissions within 6 months before the first dialysis treatment.

Hospitalizations {#section32-2054358118780372}
----------------

During the study period, there were 112 374 hospitalizations, and 12 931 (11.5%) of these hospitalizations were dialysis-specific infection-related hospitalizations. Among pediatric patients (age 0-17 years), kidney disease was listed as the most responsible diagnosis for 290 (25.7%) hospitalizations and dialysis-specific infections were listed for 132 (11.7%) hospitalizations. Among patients age 18 to 64 years, kidney disease was the most responsible diagnosis for 3399 (6.2%) hospitalizations, and dialysis-specific infections were listed for 5413 (9.9%) hospitalizations. Other common most responsible diagnoses in patients age 18 to 64 years were diabetes (7908; 14.5% of hospitalizations) and cardiovascular disease (angina and myocardial infarction: 1809; 3.3% of hospitalizations). Among patients age 65 years and older, dialysis-specific infections (5140; 9.1%), diabetes (4311; 7.6%), cardiovascular disease (2975; 5.3%), and kidney disease (1823; 3.2%) were the most common most responsible diagnoses for hospitalizations.

Crude all-cause and infection-related hospitalization rates and all-cause in-hospital mortality rates by age group are presented in [Figure 1](#fig1-2054358118780372){ref-type="fig"} and [Supplementary Tables 1](http://journals.sagepub.com/doi/suppl/10.1177/2054358118780372) to [3](http://journals.sagepub.com/doi/suppl/10.1177/2054358118780372). The all-cause hospitalization rate was similar for the 3 adult age groups and declined slightly over time (age 65 years and older: 1.40, 1.35, and 1.18 admissions PPY at 7 days, 30 days, and 6 months postdialysis initiation). Compared with all adult age groups, the all-cause hospitalization rate for pediatric patients was slightly higher at 7 days postdialysis initiation (1.67 admissions PPY), increased thereafter, and remained much higher over time (2.48 and 2.47 admissions PPY at 30 days and 6 months postdialysis initiation, respectively). Within the first 30 days of dialysis initiation, the infection-related hospitalization rate in pediatric patients consistently increased, surpassing the rate in all adult age groups at \>30 days postdialysis initiation (ages 0-17 years: 0.00 PPY at 7 days, 0.13 PPY at 30 days, 0.21 PPY at 6 months; ages 45-64 years: 0.12 PPY at 7 days, 0.13 PPY at 30 days, 0.12 PPY at 6 months). The infection-related hospitalization rate was similar across all adult age groups and remained stable over time. The all-cause in-hospital mortality rate was highest in elderly (age ⩾65) dialysis patients and lowest in pediatric patients over the entire follow-up (at 1 year; ages 0-17 years: 0.01 PPY, age 65 years and older: 0.13 PPY).

![Crude hospitalization and in-hospital mortality rates over time by age group.](10.1177_2054358118780372-fig1){#fig1-2054358118780372}

Risk Factors for Hospitalization {#section33-2054358118780372}
--------------------------------

The adjusted HRs for all-cause and infection-related hospitalizations for each covariate of interest are presented in [Table 2](#table2-2054358118780372){ref-type="table"}. The HRs for dialysis modality as a time-varying covariate are presented separately in [Figure 2](#fig2-2054358118780372){ref-type="fig"} and [Supplementary Table 4](http://journals.sagepub.com/doi/suppl/10.1177/2054358118780372). Compared with dialysis patients age 45 to 64 years (referent), pediatric patients (HR: 2.73, 95% confidence interval \[CI\]: 2.37-3.15) and 18- to 44-year-old patients (HR: 1.21, 95% CI: 1.15-1.27) had a higher risk of all-cause hospitalization. Patients age 65 to 74 years had a lower risk (HR: 0.95, 95% CI: 0.91-0.98). When limited to infection-related hospitalization, the trends were similar, though not statistically significant. Female dialysis patients had a higher risk of all-cause hospitalization (HR: 1.08, 95% CI: 1.05-1.11) but not infection-related hospitalization. Compared with Caucasians, Indigenous patients had a higher risk of all-cause hospitalization (HR: 1.20, 95% CI: 1.12-1.28), while other races had a lower risk. The risk of infection-related hospitalization was significantly higher in Indigenous patients (HR: 1.30, 95% CI: 1.11-1.53) and lower in Asian patients (HR: 0.76, 95% CI: 0.65-0.89) compared with Caucasians. Patients with ESKD secondary to diabetes were at increased risk, and patients with congenital or hereditary kidney disease were at lower risk for all-cause and infection-related hospitalizations compared with patients with glomerulonephritis. Patients who had dialysis treatments at home were at lower risk for all-cause hospitalization (HR: 0.84, 95% CI: 0.79-0.88) and infection-related hospitalization. Every week spent in hospital in the 6 months prior to dialysis initiation increased the risk of all-cause hospitalization following dialysis initiation by 2% and infection-related hospitalization by 5%. Patients on HD and PD had a decline in the risk of all-cause hospitalization over time (HD: HRs 0.76 and 0.53 at 8-30 days and 6-12 months respectively; PD: HRs 0.73 and 0.56 at 8-30 days and 6-12 months respectively; referent group: HD at ⩽7 days). Within the first 7 days after dialysis initiation, patients on PD had a higher risk of all-cause hospitalization (HR: 1.27, 95% CI: 1.07-1.50) and infection-related hospitalization (HR: 2.05, 95% CI: 1.19-3.55).

###### 

Risk Factors for Hospitalization.

![](10.1177_2054358118780372-table2)

  ------------------------------------------------------------------------------------------------------------------------------------------
                                                                           All-cause hospitalization\   Infection-related hospitalization\
                                                                           Adjusted HR (95% CI)         Adjusted HR (95% CI)
  ------------------------------------------------------------------------ ---------------------------- ------------------------------------
  Age group                                                                                             

   0-17                                                                    2.73 (2.37-3.15)             1.30 (0.90-1.88)

   18-44                                                                   1.21 (1.15-1.27)             1.03 (0.90-1.16)

   45-64                                                                   Referent                     Referent

   65-74                                                                   0.95 (0.91-0.98)             0.96 (0.88-1.06)

   ⩾75                                                                     1.01 (0.97-1.05)             1.02 (0.92-1.12)

  Sex                                                                                                   

   Female                                                                  1.08 (1.05-1.11)             1.03 (0.96-1.11)

  Race                                                                                                  

   Asian                                                                   0.72 (0.68-0.77)             0.76 (0.65-0.89)

   Indian subcontinent                                                     0.78 (0.73-0.84)             0.86 (0.73-1.02)

   Indigenous                                                              1.20 (1.12-1.28)             1.30 (1.11-1.53)

   Black                                                                   0.86 (0.80-0.93)             0.98 (0.81-1.18)

   Caucasian                                                               Referent                     Referent

  Income quintile^[a](#table-fn8-2054358118780372){ref-type="table-fn"}^                                

   5 (high)                                                                1.02 (0.97-1.06)             1.07 (0.95-1.20)

   4                                                                       0.96 (0.92-1.01)             0.98 (0.87-1.09)

   3                                                                       0.97 (0.93-1.01)             1.00 (0.90-1.12)

   2                                                                       0.98 (0.94-1.02)             1.05 (0.95-1.17)

   1 (low)                                                                 Referent                     Referent

  Dialysis care location                                                                                

   Home                                                                    0.84 (0.79-0.88)             0.85 (0.75-0.97)

  Cause of ESKD                                                                                         

   Glomerulonephritis                                                      Referent                     Referent

   Diabetes                                                                1.17 (1.11-1.22)             1.17 (1.03-1.33)

   Renal vascular disease                                                  1.00 (0.95-1.06)             0.95 (0.82-1.09)

   Congenital/hereditary                                                   0.92 (0.85-0.99)             0.78 (0.64-0.95)

  Comorbidities                                                                                         

   Cardiovascular disease                                                  1.14 (1.10-1.18)             1.05 (0.96-1.14)

   Congestive heart failure                                                1.13 (1.09-1.17)             1.04 (0.95-1.14)

   Cerebrovascular disease                                                 1.06 (1.01-1.10)             1.07 (0.96-1.19)

   Peripheral vascular disease                                             1.16 (1.12-1.21)             1.17 (1.06-1.29)

   Diabetes^[b](#table-fn9-2054358118780372){ref-type="table-fn"}^         1.10 (1.05-1.15)             1.27 (1.13-1.42)

   Malignancy                                                              1.21 (1.16-1.26)             1.19 (1.07-1.33)

   COPD                                                                    1.15 (1.10-1.21)             1.21 (1.08-1.36)

   Hypertension                                                            0.90 (0.87-0.94)             0.84 (0.76-0.93)

  Predialysis hospitalization                                                                           

   Every week in hospital prior to dialysis start                          1.02 (1.02-1.03)             1.05 (1.04-1.06)
  ------------------------------------------------------------------------------------------------------------------------------------------

*Note.* HR = hazard ratio; CI = confidence interval; ESKD = end-stage kidney disease; COPD = chronic obstructive pulmonary disease.

Patient level household income is an estimate using neighborhood income levels.

The diabetes comorbidity covariate excludes patients with a primary ESKD diagnosis of diabetes.

![Comparative risk of hospitalization over time by modality type.](10.1177_2054358118780372-fig2){#fig2-2054358118780372}

Discussion {#section34-2054358118780372}
==========

In this analysis of 38 369 incident chronic dialysis patients in Canada with 112 374 hospitalizations, we found that many hospitalizations (11.5%) were attributable to dialysis-specific infections. We were able to characterize risk factors for hospitalization, including Indigenous race, female sex, and younger age. Patients on PD had a significantly higher risk of all-cause and infection-related hospitalizations within the first 7 days of dialysis initiation. Beyond 7 days, the risk of hospitalization did not differ significantly by dialysis modality, but there was a trend toward an increased risk of infection-related hospitalization in patients on PD. The all-cause hospitalization rate was time-dependent and noted to be highest shortly after starting dialysis.

The hospitalization rates in our study of Canadian dialysis patients are comparable but slightly lower than those described in the most recent reports from the USRDS.^[@bibr6-2054358118780372],[@bibr15-2054358118780372]^ In our study, adult patients had a hospitalization rate ranging from 1.1 to 1.4 PPY. Comparatively, the USRDS reported a rate for patients on HD and PD of 1.7 and 1.6 hospitalizations PPY, respectively.^[@bibr6-2054358118780372]^ European countries participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS) reported a lower hospitalization rate for patients on HD of 0.99 PPY. However, this is a point prevalent rate, which may explain why the DOPPS rate is lower.^[@bibr16-2054358118780372]^ Similar to our study, the USRDS reported a higher hospitalization rate in pediatric dialysis patients (2.0 PPY).^[@bibr6-2054358118780372]^ Our hospitalization rate for elderly dialysis patients (⩾65 years) is similar to a prior American study that reported a rate of 1.5 PPY.^[@bibr17-2054358118780372]^ We report an infection-related hospitalization rate in adult patients of 0.08 to 0.13 PPY, which is slightly higher than a prior study that examined dialysis patients in Quebec, Canada, and reported a rate of 0.05 PPY for dialysis-specific infectious hospitalizations.^[@bibr8-2054358118780372]^ The decline in hospitalization risk seen with increasing age is likely at least partly explained by the competing risk of death.

We found a higher risk of all-cause hospitalization in patients on PD compared with patients on HD during the first 7 days on dialysis. The risk for infection-related hospitalization in patients on PD was particularly high during this initial time period on dialysis. This increased risk in patients on PD is consistent with a prior study demonstrating that most hospitalizations and episodes of peritonitis in patients on PD occur within the first 6 months on dialysis.^[@bibr18-2054358118780372]^ Our finding of a higher risk of infection-related hospitalization in patients on PD is consistent with prior studies by Lafrance et al^[@bibr9-2054358118780372]^ and van Diepen et al,^[@bibr19-2054358118780372]^ but not consistent with a study by Williams et al^[@bibr11-2054358118780372]^ that showed no difference between patients on HD and PD, and a study by Quinn et al^[@bibr10-2054358118780372]^ that showed an increased risk in patients on HD. Discrepant results between studies could be due to a number of reasons. Risk may vary across jurisdictions due to differing practice patterns. Failure to examine risk by time on dialysis could alter results; our results show that the risk of infection-related hospitalization in patients on PD lowers once on dialysis for greater than a week. This initial higher risk may be a true association but may also be explained by the fact that more patients initiate HD (rather than PD) during a hospitalization. If a patient were already hospitalized at the time of dialysis initiation (admission date prior to or on dialysis start date), this would be captured as a predialysis hospitalization, and the patient would not be at risk for a hospitalization event until after discharge. Failure to treat dialysis modality as a time dependent covariate could affect results, as patients often change dialysis modality over time. The definition of infection-related hospitalization is also important. Some studies included nondialysis related infections in the definition of infection-related hospitalization. Patients on PD may be at decreased risk for pneumonia but increased risk for dialysis-related infections,^[@bibr9-2054358118780372],[@bibr19-2054358118780372]^ highlighting the importance of reporting dialysis and nondialysis infection-related hospitalizations separately. Rates could also differ across studies depending on how study populations are defined (ie, incident vs prevalent dialysis patients).

We found that Indigenous dialysis patients were at increased risk for hospitalizations. Potential reasons for this could include socioeconomic factors, geographic isolation limiting access to medical care, and comorbidity burden. A study in the United States found that Indigenous patients were more likely to miss or shorten HD treatments and that doing so had an escalating effect on hospitalization rates.^[@bibr20-2054358118780372],[@bibr21-2054358118780372]^ Contrary to our findings, the 2017 USRDS report did not find that Indigenous dialysis patients were at increased risk for hospitalizations; however; the USRDS analysis by race did not include patients on PD, which could potentially explain the discrepant results.^[@bibr15-2054358118780372]^ A study from the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) found that Indigenous patients on PD living in remote areas had a higher risk of PD-related complications.^[@bibr22-2054358118780372]^ We did not specifically examine this subgroup, but a high hospitalization rate in this group of patients could be one of the factors driving the increased hospitalization risk in Canadian Indigenous patients. We also found that female patients were at higher risk. The reasons for this requires further study, but this finding was also highlighted in the 2017 USRDS report, where a 17.5% higher hospitalization rate was reported for female compared with male HD patients.^[@bibr15-2054358118780372]^

Reporting on hospitalizations in dialysis patients is important to inform strategies to reduce preventable hospitalizations and readmissions. The United States has long been tracking hospitalizations in dialysis patients and has reported a 19% decline from 2005 to 2014.^[@bibr6-2054358118780372]^ This is the first national study of hospitalizations in dialysis patients in Canada and highlights the need for further studies to determine strategies that may reduce hospitalizations for incident dialysis patients. Proposed strategies may include enhanced monitoring by health care professionals, ensuring patients on home dialysis are properly trained, and appropriately following guidelines for the prevention of dialysis access--related infections.^[@bibr4-2054358118780372],[@bibr23-2054358118780372][@bibr24-2054358118780372][@bibr25-2054358118780372][@bibr26-2054358118780372][@bibr27-2054358118780372]-[@bibr28-2054358118780372]^ Among patients on HD, strategies aimed at increasing arteriovenous fistula (AVF) use may help to reduce infection-related hospitalizations. An international study using DOPPS data from 20 countries found that Canada had the lowest AVF use at 49% and the highest central venous catheter use at 45%.^[@bibr29-2054358118780372]^ Our study also highlights the important issue of hospitalizations in pediatric dialysis patients, with a large proportion of hospitalizations primarily due to kidney-related or dialysis-related problems. This is clearly a unique patient population with its own set of challenges compared with the adult ESKD population. In addition to enhanced monitoring, education, and infection prevention measures, strategies such as increased uptake of frequent home HD for improved volume control may help to reduce admissions.^[@bibr30-2054358118780372]^ Aggressively minimizing time spent on dialysis by optimizing access to kidney transplantation should also be a key objective in pediatric patients. Overall, there is a paucity of data on hospitalizations in pediatric patients; further study is needed to understand this important issue.

Our study has important limitations. The cohort had too few home HD patients to examine this subgroup. Patients on home HD have been previously found to have a lower risk of hospitalizations compared with patients on PD, and a lower risk of cardiovascular hospitalizations but higher risk of infection-related hospitalizations.^[@bibr30-2054358118780372][@bibr31-2054358118780372]-[@bibr32-2054358118780372]^ Characteristics previously found to be associated with hospitalizations, such as frailty, serum ferritin, and serum sodium, were not examined.^[@bibr33-2054358118780372][@bibr34-2054358118780372][@bibr35-2054358118780372]-[@bibr36-2054358118780372]^ Data on patient adherence with prescribed treatments and individual dialysis prescriptions were also not available. The outcome of infection-related hospitalization was determined using diagnostic codes with uncertain validity. We did not have access to culture results or clinical data to confirm the diagnosis of a dialysis-related infection.

Conclusions {#section35-2054358118780372}
===========

This national study highlights the important issue of hospitalizations in chronic dialysis patients. The rates of hospitalization were not influenced by dialysis modality beyond the initial 7 days following dialysis initiation. Pediatric, Indigenous, and female patients are at higher risk for hospitalizations, and the initial weeks postdialysis initiation represent a high-risk transitional period.

Supplemental Material {#section36-2054358118780372}
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